I’ve thought about that quite a bit, given the clues about Reata being a base case the balancing act would be enormous, they not only have to buy out NEU but also have the final development costs and approvals so it’s not just a buyout but pretty hefty approvals costs, can their current cash flow models support that? At least they wouldn’t have to be paying NEU anymore, also would the ACAD SP take a hit due to the dilution involved? Lot’s of questions that are above my grade.
NEU Price at posting:
$12.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)